Homologus PRP in the Infiltrative Treatment of Knee Osteoarthritis in Young Athletic Patients

Launched by ISTITUTO ORTOPEDICO RIZZOLI · Jul 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for knee osteoarthritis, a condition that causes pain and stiffness in the knee, especially in young athletes aged 18 to 40. The focus is on using a specific type of treatment called homologous platelet-rich plasma (PRP) injections to see how effective it is in reducing pain and improving function. To be eligible for this trial, participants must have knee osteoarthritis affecting one knee, show signs of cartilage damage on scans, and have a pain level of 4 or higher on a simple scale.

Participants in the trial will go through a few steps: first, they’ll be evaluated by orthopedic specialists and complete some questionnaires. Then, they’ll receive the treatment, and afterwards, medical staff will check in with them at 1, 3, 6, and 12 months to see how they’re doing. This includes more questionnaires to assess their pain and any side effects from the treatment. It’s important to note that certain conditions, like recent knee surgeries or serious health issues, may prevent someone from joining the trial. Overall, this study aims to provide insights into a potential new treatment option for young people dealing with knee osteoarthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients, both sexes, with symptomatic knee osteoarthritis with:
• • Age: 18-40 years;
• • Unilateral involvement;
• • Signs and symptoms of knee osteoarthritis;
• • Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);
• • Ability and consent of patients to actively participate in clinical follow-up;
• • Signature of informed consent;
• • Pain ≥ 4 on VAS s
• Exclusion Criteria:
• • Patients unable to express consent;
• • Patients undergoing intra-articular infiltration of other substance in the previous 6 months;
• • Patients undergoing knee surgery in the previous 12 months;
• • Patients with malignant neoplasms;
• • Patients with rheumatic diseases;
• • Patients with uncontrolled metabolic diseases;
• • Patients with hematological diseases (coagulopathies);
• • Patients abusing alcoholic beverages, drugs or medications;
• • Knee trauma treated in the previous 6 months.
• • Other conditions that may interfere with the evaluation of OA treatment.